Asthma | Treatment Algorithms: Claims Data Analysis | Adult Asthma | US | 2025
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA). Maintenance therapies are inhaled, oral, or biological drugs (e.g., a LABA / ICS such as GSK’s Advair; an anti-IL-5 agent such as AstraZeneca’s Fasenra) that are used to prevent exacerbations by targeting the underlying disease pathophysiology. Many adult patients receive several agents to treat their asthma. Although multiple well-established therapies are available for adult asthma, the market has seen the approval and launch of even more agents, including novel biologics (e.g., AstraZeneca’s Tezspire) and generic versions of blockbuster inhaled drugs (e.g., albuterol sulfate, formoterol / budesonide). These launches have added treatment options and intensified the competition in this market.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult asthma patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult asthma patients?
- How has Sanofi / Regeneron’s Dupixent been integrated into the treatment algorithm, and what is its source of business?
- What percentage of adult asthma patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of adult asthma patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Content highlights
Markets covered: United States
Key companies: GlaxoSmithKline, AstraZeneca, Teva, Genentech, Merck, Boehringer Ingelheim, Sanofi, Regeneron, Mylan, Cipla, Par, Perrigo, Prasco
Key drugs: Advair, Symbicort, Breo, ProAir, Xolair, Dupixent, Nucala, Fasenra, Tezspire, Spiriva, Trelegy
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Solution enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
